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Abstract
Background: Tumor-positive sentinel lymph node (SLN) biopsy results in a risk of non sentinel node metastases
in micro- and macro-metastases ranging from 20 to 50%, respectively. Therefore, most patients underwent
unnecessary axillary lymph node dissections. We have previously developed a mathematical model for predicting
patient-specific risk of non sentinel node (NSN) metastases based on 2460 patients. The study reports the results
of the validation phase where a total of 1945 patients were enrolled, aimed at identifying a tool that gives the
possibility to the surgeon to choose intraoperatively whether to perform or not axillary lymph node dissection
(ALND).
Methods: The following parameters were recorded: Clinical: hospital, age, medical record number; Bio
pathological: Tumor (T) size stratified in quartiles, grading (G), histologic type, lymphatic/vascular invasion (LVI),
ER-PR status, Ki 67, molecular classification (Luminal A, Luminal B, HER-2 Like, Triple negative); Sentinel and non-
sentinel node related: Number of NSNs removed, number of positive NSNs, cytokeratin 19 (CK19) mRNA copy
number of positive sentinel nodes stratified in quartiles. A total of 1945 patients were included in the database.
All patient data were provided by the authors of this paper.
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Results: The discrimination of the model quantified with the area under the receiver operating characteristics (ROC)
curve (AUC), was 0.65 and 0.71 in the validation and retrospective phase, respectively. The calibration determines
the distance between predicted outcome and actual outcome. The mean difference between predicted/observed
was 2.3 and 6.3% in the retrospective and in the validation phase, respectively. The two values are quite similar and
as a result we can conclude that the nomogram effectiveness was validated. Moreover, the ROC curve identified in
the risk category of 31% of positive NSNs, the best compromise between false negative and positive rates i.e. when
ALND is unnecessary (<31%) or recommended (>31%).
Conclusions: The results of the study confirm that OSNA nomogram may help surgeons make an intraoperative
decision on whether to perform ALND or not in case of positive sentinel nodes, and the patient to accept this
decision based on a reliable estimation on the true percentage of NSN involvement. The use of this nomogram
achieves two main gools: 1) the choice of the right treatment during the operation, 2) to avoid for the patient a
second surgery procedure.
Keywords: Nomogram, Non Sentinel Node status, OSNA method, CK19 mRNA number copies
Background
In the treatment of breast cancer patients sentinel lymph
node (SLN) biopsy is a highly accurate predictor of overall
axillary status. It has become the standard axillary staging
method for the last 15 years in breast cancer (BC) patients
who are confirmed clinically negative for lymph node me-
tastases [1, 2]. In the case of negative SLN, patients can
safely avoid axillary lymph node dissection (ALND), thus
preventing associated morbidity [3]. However, approxi-
mately 50–70% of patients with positive SLN have no add-
itional positive nodes, suggesting that it may be possible to
avoid ALND in selected patients [4, 5]. Taking these con-
siderations into account, an accurate estimate of the likeli-
hood of additional node metastases may be of paramount
importance when deciding further treatment. At present,
the intra-operative decision on, whether to perform ALND
or not, is often only based on the positivity of the SLN. In
order to assess the SLN status more rapidly, a semi-
automated molecular method called the one step nucleic
acid amplification (OSNA) assay has recently been made
available [6, 7]. As a matter of fact this method is able to
assess the entire SLN in thirty minutes. On the basis of
these considerations, the European OSNA Committee de-
cided to develop a new nomogram able to predict the non
sentinel node (NSN) status, aimed at identifying a tool that
gives the possibility to the surgeon to choose intraoperativ-
ily whether to perform or not axillary lymph node dissec-
tion (ALND). A total of 2460 patients were enrolled in the
retrospective phase of the nomogram elaboration. The
multivariate analysis demonstrated that only the number
of CK19 copies (p < 0.0001) and T size (p < 0.0001) were
associated with the NSN metastases. Therefore, a nomo-
gram was developed using these two parameters stratified
in quartiles. The score of each of the two variables
summed and reported in on the total raw score immedi-
ately below the percentage of NSN positivity is identified
[8]. The aim of the study was to report the results of the
validation phase comprising a total of 1495 enrolled pa-
tients (the retrospective phase was already published). The
study was conducted with the support of 22 European
centers that did not requested any financial support.
Methods
Patients’ population
The European OSNA Users Committee decided to carry
out the validation phase of the nomogram project with the
following aims: To verify the effectiveness of the nomo-
gram to help surgeons in deciding whether to carry out
ALND in case of positive SLN; to identify patients at very
low risk of positive NSNs in which ALND may be avoided.
Our study population only included cases that fulfilled the
following criteria: primary invasive cT1-3 BC with clinically
and radiological (preoperative sonogram) negative axilla;
no prior systemic treatment, or axillary surgery; successful
SLN biopsy in which metastatic disease was identified by
OSNA; and ALND with at least 10 nodes examined. The
following parameters were recorded: Clinical: hospital, age,
medical record number; Bio-pathological: tumor size strati-
fied in quartiles, grading, multifocality, histological type,
LVI, ER-PR status, HER-2, ki67, molecular classification
(luminal A, luminal B, HER2 like, triple negative); SLN and
NSN related: number of removed SLNs, number of posi-
tive and negative SLNs, copy number of positive SLNs. A
total of 2460 patients were included in the database in the
retrospective phase. Seventeen European centers contrib-
uted in the retrospective enrollment of patients in the val-
idation phase up to a total of 1495 patients.
The biopathological parameters and the characteristics
of SN and NSN are shown in Tables 1 and 2.
LVI was excluded because the aim of the nomogram is
to give the possibility to the surgeon to intra operatively
establish whether to perform ALND or not and this par-
ameter cannot be assessed reliably in the preoperative
breast cancer biopsy.
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Sentinel Lymph Node (SLN) sampling method
SLNs were identified using technetium 99 m- labeled,
nanosized, human serum albumin colloids. To avoid any
contamination during tumor manipulation, SLNs were
surgically excised before breast surgery and sent on ice to
the Pathology Department. Each SLN was weighed and
measured. SLNs weighing less than 50 mg were excluded
from the study. SLNs weighing more than 600 mg were
cut in two or more pieces and processed as separate
nodes. The weight of lymph node for homogenization
should be within a range of 50/600 mg. If the weight of
the lymph node is either above or below this specified
range accurate results may not been obtained.
One Step Nucleic Acid Amplification (OSNA)
The OSNA assay was performed according to the manu-
facturer’s instructions (Sysmex, Kobe, Japan). In short,
the SLN was homogenized in 4 ml of the LINORHAG
homogenizing buffer (Sysmex) on ice. A small aliquot
was used for automated real-time amplification of CK19
mRNA via reverse transcription loop-mediated isother-
mal amplification (RT-LAMP) with the ready-to use
LYNOAMP reagent kit (Sysmex) on the RD-100i (Sys-
mex). It was possible to analyze up to 4 SLNs in one run.
The degree of amplification was detected via a bypro-
duct of the reaction, i.e. magnesium-pyrophosphate.
After use, the excess lysate was stored at minus 80 °C.
A lysate with CK19 mRNA copy number/μl less than
250 (a) was regarded as negative (score−); from 250 to
5000 (b) as positive (score +), and greater than 5000 (c)
(score ++). The OSNA results were immediately com-
municated to the surgeon by telephone within 30–
40 min. For statistical analysis, in case of two or more
SLNs, the SLN with the greatest CK19 mRNA copies
was chosen. When there was a positive OSNA result,
both for micro-metastases (+) and macro-metastases (++),
the patients underwent an immediate ALND. ITCs are
not detected by the OSNA method. This is not a limita-
tion because patients with positive SLNs for ITC are no
longer referred to undergo ALND.
Axillary NSNs were routinely examined by H&E.
Statistical method
The outcome of our nomogram was the presence of
positive nodes in the axillary dissections following
Table 1 Clinicopathological characteristics of patients
Characteristics N of patients Percent
Histology
IDL 1278 85.5
ILC 184 12.3
Other 33 2.2
Grading
G1 129 8.6
G2 827 55.4
G3 490 32.8
Unk 49 3.2
ER
Pos 1297 86.7
Neg 147 9.8
Unk 51 3.4
PgR
Pos 1174 78.5
Neg 268 17.9
Unk 53 3.5
HER2
Pos 147 9.8
Neg 927 62.0
Unk 421 28.2
Ki67
Low 876 58.6
High 515 34.4
Unk 104 7.0
T
≤ 12 398 26.6
≥ 13–18 364 24.3
≥ 19–25 400 26.8
> 25 333 22.3
Type
Multiple 364 24.3
Single 1131 75.7
Molecular subtype
Luminal A 452 30.2
Luminal B 628 42.0
HER2-like 50 3.3
Triple Negative 58 3.9
Unk 307 20.5
Table 2 Characteristics of non sentinel node and sentinel node
Number Percent
NSLNs Examined
Median (range) 15 (11–52)
N° of positive NSLNs 610 40.8
Median (range) 2 (1–41)
N° of Copies (Highest copy number)
≤ 1500 305 20.4
> 1500–12,000 329 22.0
> 12,000–111,000 460 30.8
> 111,000 401 26.8
Di Filippo et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:193 Page 3 of 9
OSNA evaluation in the population defined above. In
order to validate the retrospective phase of the nomo-
gram we have considered the covariates that predicted
this outcome in the previous published paper [8], thus
the endpoint was a binary outcome (presence versus ab-
sence of at least one positive node other than SLN) and
the association with the covariates was analyzed using a
logistic linear model. Discrimination ability was assessed
by ROC analysis and predictive accuracy was measured
by the AUC reported with its 95% confidence interval.
Calibration was evaluated by reviewing the plot of pre-
dicted probabilities versus the actual probabilities. Well
calibrated models have a linear relationship with a slope
of 1 and an intercept of 0. Thus, a linear regression
coefficient between predicted and observed values was
estimated. The resulting model will be validated in a
prospective series. All the analyses were performed
using IBM SPSS version n. 20 [9].
Ethical consideration
Patient data was anonymously gathered retrospectively
with no influence on patient therapy. The Nomogram
project was approved by the Ethics Committee of each
participating institute.
Results
Table 1 shows the clinical and bio-pathological charac-
teristics of the patients. The mean and median ages were
55 and 54, respectively and standard deviation was 13
and range 24–80 years. The vast majority of the patients
were affected with infiltrating ductal carcinoma (85.5%).
Most of them had an intermediate (55.4%) or high grade
tumors (32.8%). Both Estrogen (ER) and Progesterone
(PgR) receptors were positive in 86.7 and 78.5%, respect-
ively, whereas HER2 was positive only in 9.8% of the pa-
tients. Ki67 was high in 34.4% and LVI was present in
24.2% of the patients. These parameters represent the
new molecular classifications of breast cancer that not
only allow to identify patients at a higher risk of relapse
but may also guide postoperative therapies [10, 11].
Tumor size was divided in quartiles, the cut-offs being
12, 18 and 25 mm. The mean and median tumor sizes
were 20.5 and 18.2 mm, respectively, ranging between
0.7 and 50 mm. The SLNs and NSLNs characteristics
are reported in Table 2. The median number of NSNs
removed with ALND is 15 (range11–52). The number of
positive NSNs was 610 (40.8%), the median value was 2
(range 1–41). The number of CK19 mRNA was divided
in quartiles in order to obtain a better stratification of
the patients. In order to validate the nomogram, we eval-
uated the discrimination of the model. This parameter
which was quantified with the area under receiver oper-
ating characteristic (ROC) curve was 0.65 (95% C.I.
0.63–0.69). Figure 1 shows the ROC curve of the valid-
ation phase, the values are quite similar being 0.71 in
the retrospective phase and 0.65 in the validation phase,
Fig. 1 ROC curve of of number of CK19 mRNA, T size (quartiles) and the model containing these two variables
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demonstrating a fair level of discrimination. Another
parameter that is usually employed to evaluate the reli-
ability of a nomogram is the calibration, that is shown
in Fig. 2. The calibration determines the distance
between predicted outcome and actual outcome. The
mean difference between predicted/observed was 2.3
and 6.3% in the retrospective and in the validation
phase, respectively. The two values are quite similar,
and consequently we can conclude that the nomogram
effectiveness was validated [8].
It is well known that SLN micro- and macro-
metastases are associated with a mean NSN positivity
rate of 20 and 50%, respectively. Consequently, the
dilemma for surgeons still persists in how to avoid
unnecessary ALND and how to identify patients at high
risk of positive NSNs in which ALND is recommended.
Given that the validation phase had been evaluated suc-
cessfully, all the patients enrolled in the retrospective
and validation phase (3955 patients were valuable for
the nomogram) were evaluated to develop a tool that
allows the surgeon to intraoperatively make a decision
on whether to perform ALND in case of positive SLN or
not. The nomogram validated the risk percentage of
NSN positivity that we recently published [8]. In Table 3,
we stratified the patients in risk categories, according
the nomogram model, from 11 to 50% and for each risk
category we calculated the percentage of false negative
and false positive rates in order to identify patients in
which ALND is unnecessary and those where ALND is
recommended. Moreover, the ROC curve identified in
the risk category of 31%, the best compromise between
false negative and positive rates. Therefore, in patients
below this cut-off ALND may be omitted, for values
higher than 31% ALND is recommended.
Discussion
Usually the effectiveness of a nomogram is evaluated with
three parameters i.e., discrimination, calibration and the
capacity of a nomogram to identify false negatives i.e. pa-
tients with a risk of NSN metastases ≤10% in which
ALND may be omitted. Discrimination (i.e. whether the
relative ranking of individual prediction is in the correct
order) was quantified with the area under curve the re-
ceiver operating characteristics (ROC) curve (AUC). The
AUC is a summary measure of the ROC that reflects the
ability of a test to discriminate between a diseased and
non-diseased subject across all the possible levels of posi-
tivity. AUC ranges from 0 to 1, with 1 indicating perfect
concordance, 0.5 indicating no better concordance than
“flip the coin”, and indicating perfect discordance.
In our nomogram, the AUCs are 0.71 and 0.65, re-
spectively that are considered a fair value of discrimin-
ation consistent with the best nomograms published so
far. This data has been confirmed by a recent publica-
tion by Van Den Hoven who reported a “Head to Head”
comparison of nine predictive tools [12]. The majority of
nomograms include tumor size, lymphovascular inva-
sion, and the size of the SLN metastases. This is very
consistent with our predictive tools in which the multi-
variate analysis selected T-size, number of mRNA copies
in the SLN (i.e.) and tumor load. The comparison of
nine predictive tools showed that the MSKCC nomo-
gram had best discrimination with an AUC of 0.69,
followed by the Stanford, Mayo and MOU models with
AUC’s of 0.66, 0.65 and 0.65, respectively. The Stanford
model has second best discrimination (AUC 0.66) and
the Mayo and MOU models are tied for third (AUC
0.65). These data confirm that the AUC’s of both retro-
spective and validation phases are perfectly consistent
Fig. 2 The model performs well and correctly at low and in high risk as shown in calibration plot. The linear regression model has a slope of 0.96
(95% C.I. 0.98/1.40) and a constant of -13.8 between predicted and actual probabilities (95%C.I. -22.9/-4.85)
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with the best nomograms published so far. Calibration
determines how far the predicted probabilities are from
the actual outcomes, that has a higher clinical signifi-
cance than discrimination. Recently, Coutant evaluated
the AUC and calibration of 9 previously published
predicted models [13]. Coutant found that two of the
nomograms were well calibrated, whereas the other two
showed differences between predicted and observed
probabilities. It was also outlined that the difference be-
tween the predicted and observed probabilities for these
nomograms range from 3 to 25%. In our nomogram, the
values were 2.3 and 6.3% for retrospective and validation
phase, respectively. Therefore, they belong to the cat-
egory of low values of the above mentioned range and
can be considered reliable. This information is of clinical
utility because it gives clinicians the opportunity to in-
form patients about the predicted probability of NSN
metastases. As far as the false negative rate is concerned,
we stratified our patients in risk categories in a range
from 11 to 50% and the percentage of false negative and
positive rates was calculated for each risk category
(Table 3). It is readily apparent that up to risk category
of 30% the false negative rate is 8.2% that is in the range
value of the false negative rate reported for SLNB tech-
nique. Therefore, up to this category surgeons may feel
comfortable in suggesting patients to not undergo
ALND and patients accepting this decision. It is worth
considering that nomograms safely avoided ALNDs in
1254 (32%). We used the ROC curve analysis to calcu-
late best level of risk category in terms of balance be-
tween false positive and negative rates. The ROC curve
identified a risk category of 31% as the optimal cut-off
that the surgeon may employ in the decision-making
process on whether ALND may be omitted (<31%) or
recommended (>31%). This value was calculated taking
into account the sensitivity and specificity of the cut-off.
If we would have chosen other cut-offs this would result
in a decrease of sensitivity or specificity, therefore this
topic has to be discussed when counseling the patients.
In fact in the risk category of 30% the false negative rate
is 8.2% which is acceptable. These considerations are to
be considered valid because in the risk categories >31%
we verified patients with a percentage of positive NSNs
of 60.2%, 63% (>45%) and 66.5% (>50%). Moreover, in
the vast majority of these patients there were more than
3 positive NSNs. In our previous paper we evaluated the
capacity of the nomogram in identifying how many false
negative patients were in the risk category of 10% only
because this parameter (together wih discrimination and
calibration) is employed to evaluate the reliability of the
nomogram, as suggested by Coutant [13].
Recently, American Society of Clinical Oncology
(ASCO) guidelines for SLNB and ALND have been pub-
lished, indicating that patients with micro- and macro-
metastases may avoid ALND based on the results of
IBCSG 23.01 and Z0011 trials [14, 15]. In the prospect-
ive randomized IBCSG23-01 trial, only those patients
with micro-metastases were randomized to either ALND
or no further treatment in patients with positive SLN.
The results of this study showed no differences between
the two arms both in terms of disease-free and of overall
survival. Some challenges, however, still exist regarding
this study. Patients accrual stopped prematurely and
only 933 out of 1960 patients were enrolled, therefore
the study was underpowered. The patient population
had a very good prognosis. In fact, sentinel tumor size
≤1 mm was present in 69% of the patients. As a result,
the incidence of additional positive NSN in axillary dis-
section group was 13%, very similar to that found in case
of ITCs metastases in SLN. This is also because the au-
thor included ITCs in the group of micro-metastases. A
strict correlation between the size of micro-metastases
(less or greater than 1 mm) and positive NSNs was
clearly demonstrated by Rahusen and Viale, respectively
[16, 17]. Their results confirm that the presence of 69%
of patients with SLN micro-metastases ≤1 mm greatly
biases the interpretation in clinical practice. The median
follow-up of 5-years is too short to assess the long term
incidence of axillary recurrence in this study of this good
prognosis group. In NSABP-B6, 20% of nodal recur-
rences after lumpectomy and 24% of nodal recurrences
after ALND and radiotherapy occurred after 5 years
[18]. In the IBCSG 23-01 study, the trialists reported
that 6681 patients were registered before surgery of
which 934 patients were randomized, indicating that
only 14% of eligible breast cancer patients met the
inclusion criteria for this study and underwent
randomization. We anticipate that this may be due to
both node negative patients and also patients with mul-
tiple positive nodes and other factors, however the
breakdown is unknown. The IBCSG 23-01 data supports
omission of ALND for the selected group of patients
with small, ER+ tumors undergoing breast conservation
with planned whole breast radiation. Omitting ALND in
SLN positive mastectomy patients and patients undergo-
ing partial breast irradiation requires further investiga-
tion. If the primary benefit to these patients primarily
through systemic adjuvant therapy and not loco-regional
therapy, based on favorable tumor biology, this would
seem like the next most logical step. However, data from
the NSABP B-32 suggest a statistically significant
Table 3 Percentage of FN and FP rates according to value risk
categories are reported
Risk Categories 11% 20% 30% 45% 50% 31%
% False negative (FN) 1% 3.5% 8.2% 18.4% 24.4% 8.9%
% False positive FP) 56.0% 45.6% 31.4% 15.6% 9.0% 30.1%
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survival disadvantage after a median follow-up of 8 years
for a subset of 611 women with occult nodal disease
[19]. Completion axillary dissection had no bearing on
this effect and axillary recurrences were equivalent. The
5 year overall survival was 94.6% versus 95.8%, the 5 year
disease-free survival was 86.4% versus 89.2% and the
5 year distant disease-free survival was 89.7% versus
92.5%, respectively, all P < 0.05. The 8 year median
follow-up of the B-32 study is longer than that reported
for IBCSG 23-01. It is important to counsel patients that
the long-term outcomes of SLN biopsy alone for micro-
metastases or ITCs disease are unknown. It is conceiv-
able that based on the IBCSG 23-01 study, patients with
favorable tumor characteristics (low T-size, ER+, post
menopausal women with low tumor burden in the SLN
are potential candidates for limited axillary surgery. In
these patients, SLN biopsy can be regarded as a “super
selective therapeutic ALND”.
Recently, the recommendation by the ASCO update
committee that ALNDs can be safely avoided in patients
with one or two SLN metastases undergoing breast con-
serving surgery with conventional whole-breast radio-
therapy (RT) is premature as it is based only on the
results of the American College of Surgeons Oncology
Group Z11 trial [14, 20]. The shortfalls include the
following: recruitment rates were poor (50% of original
target); patients recruited into the study had generally
low-risk cancers; axillary recurrence was not the prede-
fined primary trial end point; approximately 50% of
patients had micro-metastases; a significant proportion
of patients had unknown nodal disease. The two groups
had slight inequalities in several prognostic characteristics
(T stage, grade, lymph-vascular invasion), all favoring the
SLN group. Moreover, micro-metastatic-only node disease
was present in a statistically significant higher percentage
of patients in the SLN group (44.8% v 37.5%). A high
proportion of patients were lost to follow-up (21% in the
ALND group and 17% in the SLN group); there was a
significant amount of missing data, and there was no
prospective RT quality assurance program to mitigate
any bias in RT target volume definition. Recently, Goyal
outlined that the most critical issue concerning the
generalization of trial is that too many patients with can-
cers who could have met the eligibility criteria were not
represented in the cohort of patients in the trial [21].
Ultimately, the American Society of Clinical Oncology’s
recommendation that ALND can be avoided in patients
with one or two SLN macrometastases, reflecting the eli-
gibility criteria of Z11, is based on a comparison of 228
patients versus 202 patients which falls significantly
short of persuasive based evidence [21]. The perception
that the Z0011 trial has not completely convinced the
oncological community is demonstrated by the fact that
additional trials are still ongoing like POSNOC (Positive
Sentinel Node: Adjuvant Therapy Alone Versus Adju-
vant Therapy Plus Clearance or Axillary Radiotherapy)
trial and the Italian SINODAR-ONE trial that compares
SLNB vs. ALND in T1-T2 patients with positive SLN
macro-metastases [22]. In regards to the post ACOSOG
Z0011 era, another topic still needs to be clarified. Does
our new understanding of breast cancer really change
clinical practice? Recently, Guth has assessed the poten-
tial impact of Z0011 on clinical practice by testing the
applicability of its criteria to a European patient popula-
tion [23]. The author concluded that “the application of
Z0011 led to the omission of completing ALND in less
than 10% of all SLNB procedures (<6% of all surgically
treated BC patients); therefore, we do not think that the
perception of Z0011 as “practice-changing” is justified”.
In a recent paper, the Results from the Breast Surg ANZ
National Breast Cancer Audit database have been ques-
tioned for women treated between 2005 and 2010 who
would have met the entry criteria for the Z0011 Trial
[24]. A total of 64,883 of breast cancer cases were eli-
gible for analysis. 22,731 underwent breast conserving
surgery and sentinel node biopsy for invasive breast can-
cer. A total of 4482 cases (6.9%) fulfilled the criteria for
Z-11 Trial. These data seem to point out that many
patients do not fulfill the inclusion criteria for Z0011,
therefore the nomogram application is still relevant in
clinical practice. Other reports also have shown that
many patients evaluated with breast cancer may not
meet the defined eligibility criteria for avoidance of
ALND in the presence of a positive SLN [25, 26]. Rea-
sons may include tumor size, tumor biology, extra-nodal
disease, patients undergoing primary chemotherapy,
selection of mastectomy, patients treated with PBI or
desire to avoid adjuvant breast radiation after breast
conserving surgery. Moreover, there are considerations
concerning clinical and pathologic subtypes that are less
clearly defined in Z0011 trial. For example, patients with
lobular histology represented only 7% of the trial popu-
lation, consequently limiting an accurate analysis of
patients with this histologic subtype. Invasive lobular
tumors are more likely to have isolated tumor cells in
the SLN, reflecting the non-cohesive cellular characteris-
tics that often require IHC detection. [27] and are more
likely to have clinical and radiological underestimation
of disease burden]. Small-volume nodal disease may
have clinical relevance in this patient population unlike
those patients with invasive ductal histology. Consider-
ation is therefore given to this difference in biology when
we are counseling patients with invasive lobular carcin-
oma and a positive SLN in performing ALND. Another
important factor when making treatment decisions is
patient age. Patients older than 18 years of age were
eligible to enroll in Z0011. However, the median age of
study participants was 54 years in the SLND group and
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56 years in the ALND group with more than 62% of pa-
tients in each group being older than 50 years. Patient
age <50 years was one of only two factors (higher Bloom
Richardson grade) associated with local-regional recur-
rence on the multivariable analysis. There may have
been reluctance from the surgeons towards randomizing
younger patients with node-positive disease to the
SLND-only group and, as a result fewer patients were in-
cluded in the study population. All these considerations
lead to the conclusion that most patients may benefit
from OSNA nomograms in the decision-making process
on whether to perform ALND or not. At this point, we
must consider which OSNA nomogram may have an im-
pact on clinical practice, in other words how many pa-
tients with SLN are assessed with OSNA. To the best of
our knowledge, there are more than 6000 patients that
undergo OSNA positive SLN assessments each year in
Europe. Therefore, this certainly justifies the develop-
ment of the OSNA nomogram that has recently been
validated. Moreover, nomogram tools have been shown
to decrease the rate of completing axillary dissections in
a subset of women with more favorable tumor factors
with only a marginally higher recurrence rate (2% vs.
0.4% at 23–30 months) [28, 29].
As a surgeon, it is also important to realize that al-
though it may be safe to avoid ALND in an ideal setting
in which both adjuvant radiation and systemic therapies
are given, in reality not all patients do or plan to complete
all the recommended adjuvant therapies, including oral
therapies such as tamoxifen, due to the perceived or actual
side-effects of these treatments. Further study is needed to
improve our understanding of breast tumor biology in
order to identify those patients for whom less extensive
surgery will not compromise long-term oncologic out-
comes. In the mean time, patient counseling for options
on low volume axillary disease management should
address exactly what data we currently have and what re-
mains unknown. In this context, OSNA nomograms may
help surgeons in counseling patients on whether to per-
form ALND or not and aid patients to accept this decision
based on the reliable estimation of the percentage of
NSN involvement. Therefore the use of this nomogram
achieves two main goals: 1) the choice of the right
treatment during the operation, 2) to avoid for the
patient a second surgery procedure. The above major
results have to be validated in a prospective validation
study that is already ongoing.
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